Preclinical efficacy of oncolytic VSV-IFNβ in treating cancer: A systematic review

VSV-IFNβ　is made of vesicular stomatitis virus (VSV) with inserting IFNβ gene. It is an oncolytic virus which infects and kills tumor cells selectively. Inserting IFNβ is for mitigate leading synthesis of IFN and other pro-inflammatory proteins to evade innate antiviral immunity. There are 4 routes of administration: intertumoral, intraperitoneal, locoregional and intervenors for both sarcoma and carcinoma. In these treatments, there are some significant effectivities, however, it can lead neurotoxicity especially in systemically established myeloma in nude mouse model. Authors conclude that further research are necessary to fully understand the side effect and to optimize as an oncolytic virotherapeutic agent.

(NN)